151 related articles for article (PubMed ID: 31010254)
1. Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro.
Makarević J; Rutz J; Juengel E; Maxeiner S; Tsaur I; Chun FK; Bereiter-Hahn J; Blaheta RA
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31010254
[TBL] [Abstract][Full Text] [Related]
2. HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells.
Juengel E; Najafi R; Rutz J; Maxeiner S; Makarevic J; Roos F; Tsaur I; Haferkamp A; Blaheta RA
Oncotarget; 2017 Dec; 8(66):110016-110028. PubMed ID: 29299126
[TBL] [Abstract][Full Text] [Related]
3. Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells.
Makarević J; Tawanaie N; Juengel E; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
J Cell Mol Med; 2014 Jul; 18(7):1460-6. PubMed ID: 24779401
[TBL] [Abstract][Full Text] [Related]
4. HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression.
Makarević J; Rutz J; Juengel E; Maxeiner S; Mani J; Vallo S; Tsaur I; Roos F; Chun FK; Blaheta RA
Cells; 2018 Sep; 7(9):. PubMed ID: 30200497
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro.
Juengel E; Natsheh I; Najafi R; Rutz J; Tsaur I; Haferkamp A; Chun FK; Blaheta RA
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31167517
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
Vallo S; Xi W; Hudak L; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Anticancer Drugs; 2011 Nov; 22(10):1002-9. PubMed ID: 21822119
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.
Wedel S; Hudak L; Seibel JM; Makarević J; Juengel E; Tsaur I; Waaga-Gasser A; Haferkamp A; Blaheta RA
BMC Cancer; 2011 Aug; 11():375. PubMed ID: 21867506
[TBL] [Abstract][Full Text] [Related]
8. HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.
Juengel E; Nowaz S; Makarevi J; Natsheh I; Werner I; Nelson K; Reiter M; Tsaur I; Mani J; Harder S; Bartsch G; Haferkamp A; Blaheta RA
Mol Cancer; 2014 Jun; 13():152. PubMed ID: 24935000
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane as an adjunctive to everolimus counteracts everolimus resistance in renal cancer cell lines.
Juengel E; Euler S; Maxeiner S; Rutz J; Justin S; Roos F; Khoder W; Nelson K; Bechstein WO; Blaheta RA
Phytomedicine; 2017 Apr; 27():1-7. PubMed ID: 28314474
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
11. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.
Wedel S; Hudak L; Seibel JM; Juengel E; Oppermann E; Haferkamp A; Blaheta RA
Prostate; 2011 May; 71(7):722-35. PubMed ID: 20954195
[TBL] [Abstract][Full Text] [Related]
12. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
[TBL] [Abstract][Full Text] [Related]
13. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid induces autophagy by suppressing the Akt/mTOR pathway in human prostate cancer cells.
Xia Q; Zheng Y; Jiang W; Huang Z; Wang M; Rodriguez R; Jin X
Oncol Lett; 2016 Sep; 12(3):1826-1832. PubMed ID: 27588130
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
Thelen P; Krahn L; Bremmer F; Strauss A; Brehm R; Loertzer H
Int J Mol Med; 2013 Feb; 31(2):339-46. PubMed ID: 23292124
[TBL] [Abstract][Full Text] [Related]
16. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.
Tsaur I; Hudak L; Makarević J; Juengel E; Mani J; Borgmann H; Gust KM; Schilling D; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
J Cell Mol Med; 2015 Aug; 19(8):1795-804. PubMed ID: 25808196
[TBL] [Abstract][Full Text] [Related]
17. Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro.
Makarević J; Tsaur I; Juengel E; Borgmann H; Nelson K; Thomas C; Bartsch G; Haferkamp A; Blaheta RA
Life Sci; 2016 Feb; 147():137-42. PubMed ID: 26827990
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
19. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.
Wei M; Mao S; Lu G; Li L; Lan X; Huang Z; Chen Y; Zhao M; Zhao Y; Xia Q
BMC Cancer; 2018 Apr; 18(1):434. PubMed ID: 29665787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
